论文部分内容阅读
乳腺癌是我国女性最常见的恶性肿瘤之一。三阴性乳腺癌(triple negative breast cancer，TNBC)是具有特殊生物学及临床病理学特征的乳腺癌亚型，以雌激素受体(estrogen receptor，ER)、孕激素受体(progesterone receptor，PR)和人类表皮生长因子受体2(human epidermal growth factor receptor 2，HER-2)表达均为阴性为其主要特征。具有侵袭性强、进展快、生存率低和预后较其他类型乳腺癌差的特点。由于缺乏有效的内分泌治疗及靶向治疗，目前以蒽环类为基础的化疗为主，但疗效欠佳，容易早期局部复发和远处转移,同时该组肿瘤具有高度异质性，因此三阴性乳腺癌的治疗成为了研究的热点。本文将近些年来有关TNBC的治疗进展予以综述。“,”Breast cancer is one of the most common malignant tumor in women in our country. Three negative breast cancer (triple negative breast cancer, TNBC) is a special biological and clinical pathological features of breast cancer subtypes, for estrogen receptors, estrogen receptor, ER) and progesterone receptor, progesterone receptor, PR) and human epidermal growth factor receptor 2 (human epidermal growth factor receptor 2, its ehrs-2) expression were negative for the main features. With strong aggressive, quick progress, low survival rate and prognosis of the characteristics of the poor than other types of breast cancer. Due to the lack of effective endocrine therapy and targeted therapy, is based on the anthracycline-based chemotherapy is given priority to, but poor curative effect, easy early local recurrence and distant metastasis, tumor with high heterogeneity, and the group so three negative treatment for breast cancer has become the research hot spot. This article will review on the treatment of TNBC in recent years.